Form Type:  SC 13G/A
Filing Date:  2/8/2021 
CIK:  0001377121 
Address:  7707 GATEWAY BLVD., SUITE 140 
City, State, Zip:  NEWARK, California 94560-1160 
Telephone:  (510) 474-0170 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
1.11 (5.28%)  
Trade Time: 
02:44 PM EST  
Market Cap: 
Trade PTGX now with 

© 2023  
Description of Business
We are a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly known as PN-235) in different stages of development, all derived from our proprietary discovery technology platform. Our clinical programs fall into two broad categories of diseases; (i) hematology and blood disorders, and (ii) inflammatory and immunomodulatory diseases. Figure 1: Our Product Pipeline [[Image Removed: Graphic]] Rusfertide Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders and is wholly owned. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. Rusfertide mimics the effect of the natural hormone hepcidin, but with greater potency, solubility and stability.
Register and access this filing in:     

EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.